TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6818169

Group type: EXPERIMENTAL
Intervention: Phenazone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phenazone plus dextropropoxyphene
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 120
Study: 31232252

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Brain Health Workshop (BHW)
Number of subjects: 50
Study: 29440016

Group type: COMPARATOR
Intervention: Point-of-care C-reactive protein test (POC CRP)
Number of subjects: 2227

Group type: COMPARATOR
Intervention: Brief intervention to elicit parental concern combined with safety net advice (BISNA)
Number of subjects: 2227

Group type: COMPARATOR
Intervention: Combination of POC CRP and BISNA
Number of subjects: 2227

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 2227
Study: 27799585

Group type: EXPERIMENTAL
Intervention: Cyclopentolate HCL 1% applied to closed eyelids
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cyclopentolate HCL 1% applied directly to open eyelids
Number of subjects: 87
Study: 24447343

Group type: EXPERIMENTAL
Intervention: Psoriasis group (NLR and hs-CRP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Psoriasis group (AVP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Psoriasis group (CIMT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 51
Study: 22180415

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 20217230

Group type: EXPERIMENTAL
Intervention: Forensic assertive community treatment (FACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 17058272

Group type: EXPERIMENTAL
Intervention: Ultrasonography of the tibial nerve in patients with vasculitic neuropathy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ultrasonography of the tibial nerve in control subjects
Number of subjects: 8
Study: 15720933

Group type: EXPERIMENTAL
Intervention: Telephone consultations
Number of subjects: 278

Group type: COMPARATOR
Intervention: Surgery consultations
Number of subjects: 278
Study: 12086199

Group type: EXPERIMENTAL
Intervention: Flunisolide HFA (340 microg daily)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (6400 microg daily)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) (336 microg daily)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Flunisolide HFA, BDP, and Cromolyn sodium
Number of subjects: 235
Study: 10429772

Group type: EXPERIMENTAL
Intervention: Droperidol (10 micrograms x kg‐1)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Dolasetron (12.5 mg)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Combination of droperidol and dolasetron (10 micrograms x kg‐1 + 12.5 mg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 148
Study: 7593515

Group type: EXPERIMENTAL
Intervention: Microlaparoscope < 2.0 mm diameter under general anaesthesia (group I)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Microlaparoscope < 2.0 mm diameter under analgesic sedation plus local anaesthesia (group II)
Number of subjects: 41
Study: 2105990

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Budesonide (15 minutes before exercise)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Budesonide aerosol (4 weeks treatment)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 22
Study: 91498

Group type: EXPERIMENTAL
Intervention: EEG patterns during cognitive tasks
Number of subjects: 23
Study: 30891718

Group type: EXPERIMENTAL
Intervention: Intervention deprexis®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27918712

Group type: EXPERIMENTAL
Intervention: Stepped Care (SC) program
Number of subjects: 156

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 156
Study: 25719620

Group type: EXPERIMENTAL
Intervention: Paravertebral blocks (PVB) and total intravenous anesthesia
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham subcutaneous injections and standardized general anesthesia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: DN4 screening tool
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IASP grading system
Number of subjects: 66
Study: 24977310

Group type: COMPARATOR
Intervention: 6-session family-based HIV prevention intervention targeting general parenting, gender roles, and parent-youth communication about sex.
Number of subjects: 99
Study: 21615424

Group type: EXPERIMENTAL
Intervention: Good side effects with positive character description
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Side effects consistent with character and motives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 19514478

Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cages (titanium interbody implants)
Number of subjects: 55
Study: 17576071

Group type: EXPERIMENTAL
Intervention: C1‐INH (1000 UI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 80
Study: 15139169

Group type: EXPERIMENTAL
Intervention: Protective equipment
Number of subjects: 301
Study: 11952432

Group type: EXPERIMENTAL
Intervention: 0.2 microg/kg/min remifentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.3 microg/kg/min remifentanil
Number of subjects: 30
Study: 9615498

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine
Number of subjects: 425
Study: 8591720

Group type: EXPERIMENTAL
Intervention: 30 mg 14C-labeled meloxicam (intravenous infusion)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 30 mg 14C-labeled meloxicam (oral solution)
Number of subjects: 4
Study: 2649022

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (20 ml containing 9% gamma-linolenic acid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 18
Study: 897632

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 0
Study: 29544520

Group type: EXPERIMENTAL
Intervention: Self-reported contraception use
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Calendar data on effective contraception use
Number of subjects: 50
Study: 28302958

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 855
Study: 25590186

Group type: EXPERIMENTAL
Intervention: Early double-guidewire (EDG) technique
Number of subjects: 274

Group type: COMPARATOR
Intervention: Repeated single-guidewire (RSG) technique
Number of subjects: 274
Study: 23296464

Group type: EXPERIMENTAL
Intervention: TruScreen
Number of subjects: 181

Group type: COMPARATOR
Intervention: Pap smear
Number of subjects: 181

Group type: COMPARATOR
Intervention: Comparison of TruScreen to Pap smear
Number of subjects: 181
Study: 21193343

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18504873

Group type: EXPERIMENTAL
Intervention: Walking exercises
Number of subjects: 79

Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 79
Study: 16630342

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture (acupuncture at non-specific points)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 14577658

Group type: EXPERIMENTAL
Intervention: CLA supplementation (2.1 g daily for 45 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11320440

Group type: EXPERIMENTAL
Intervention: Auditory confrontation naming using digitized environmental sounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free classification task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constrained classification task
Number of subjects: 0
Study: 8923023

Group type: EXPERIMENTAL
Intervention: Supplements of vitamins (with or without other antioxidants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary fibre and/or a low-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary modifications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium supplements
Number of subjects: 0
Study: 1738797

Group type: EXPERIMENTAL
Intervention: Single dose of theophylline (400 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repeated doses of theophylline (300 mg b.d. for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6395773

Group type: EXPERIMENTAL
Intervention: Prednisolone 0.75 mg/kg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prednisolone 1.25 mg/kg/day
Number of subjects: 50
Study: 30736773

Group type: EXPERIMENTAL
Intervention: Additional periarticular injection (40 mg methylprednisolone, 150 mg ropivacaine, 0.1 mg epinephrine)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No additional injection
Number of subjects: 43
Study: 29248359

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa enzyme replacement therapy (ERT), administered weekly for 96 weeks.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa ERT (continuously treated patients), administered weekly for 96 weeks.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group from Morquio A Clinical Assessment Program (MorCAP), untreated cohort, N=94.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Comparison between MOR-005 and MorCAP for mobility and self-care domains at 2 years.
Number of subjects: 173
Study: 27156854

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline (placebo)
Number of subjects: 24
Study: 26488319

Group type: EXPERIMENTAL
Intervention: Fifth intercostal space (ICS), anterior axillary line (AAL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Second intercostal space (ICS), midclavicular line (MCL)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both sites (Fifth ICS AAL and Second ICS MCL)
Number of subjects: 25
Study: 23207729

Group type: EXPERIMENTAL
Intervention: cilostazol and ozagrel for 14 days (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ozagrel alone for 14 days (n = 50)
Number of subjects: 100
Study: 21492498

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Risperidone 1 mg
Number of subjects: 40
Study: 18444492

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) - 10 units injected into both nasal cavities
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) - 3x2 injections into both nasal cavities for 4 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo - intranasal physiologic saline
Number of subjects: 38
Study: 17294999

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 50 mg lidocaine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 microg/kg remifentanil
Number of subjects: 44

Group type: COMPARATOR
Intervention: 3 ml of 0.9% sodium chloride (control group)
Number of subjects: 44
Study: 12712868

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 60
Study: 10721318

Group type: EXPERIMENTAL
Intervention: 0.35 mm copper filtration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no copper filtration)
Number of subjects: 20
Study: 8874914

Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block (DPNB) only (Group A, n = 122)
Number of subjects: 250

Group type: COMPARATOR
Intervention: General Anaesthesia (GA) + DPNB (Group B, n = 128)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: DPNB only (Group A)
Number of subjects: 250

Group type: COMPARATOR
Intervention: GA + DPNB (Group B)
Number of subjects: 250
Study: 7930473

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (INTRON A, Schering‐Plough Corporation) 5 million unit subcutaneously, three times a week for 24 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Interferon alpha‐2b with prednisolone in decreasing doses of 60, 40, 20 mg for 6 weeks
Number of subjects: 56
Study: 3332914

Group type: EXPERIMENTAL
Intervention: ciladopa 15 mg b.i.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ciladopa 5 mg b.i.d.
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ciladopa
Number of subjects: 32
Study: 29860362

Group type: EXPERIMENTAL
Intervention: Social modeling of side effects (placebo treatment)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Female participants seated with a female model
Number of subjects: 96
Study: 26319220

Group type: EXPERIMENTAL
Intervention: Sennoside
Number of subjects: 131

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 131

Group type: COMPARATOR
Intervention: PEG
Number of subjects: 131
Study: 25505230

Group type: EXPERIMENTAL
Intervention: POLE-mutant ECs
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: POLE-mutant ECs (grade 3 tumors)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: POLE-mutant ECs (from additional series)
Number of subjects: 788
Study: 24713545

Group type: EXPERIMENTAL
Intervention: AEZS-108 (267mg/m², equimolar to 76.8mg/m² of free doxorubicin) every 3 weeks as a two-hour i.v. infusion
Number of subjects: 42
Study: 22167127

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Breaks in sedentary time (BST)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Volume of sedentary time at baseline
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Baseline BST
Number of subjects: 528
Study: 20151839

Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg once or twice daily) with zidovudine-lamivudine
Number of subjects: 721

Group type: COMPARATOR
Intervention: Efavirenz (600 mg once daily) with zidovudine-lamivudine
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg once or twice daily)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Efavirenz (600 mg once daily)
Number of subjects: 721
Study: 18628619

Group type: EXPERIMENTAL
Intervention: Integrated care model (IC)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study: 15896918

Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone suppression test (DST) in BPD patients with comorbid PTSD
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.5 mg dexamethasone suppression test (DST) in total BPD group
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.5 mg dexamethasone suppression test (DST) in healthy controls
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone suppression test (DST) in BPD patients without PTSD
Number of subjects: 21
Study: 11941237

Group type: EXPERIMENTAL
Intervention: Greenbaum's method (subtenon anesthesia using a flexible plastic cannula)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ripart's method (subtenon anesthesia using a 23G hypodermic needle)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both methods (Greenbaum's and Ripart's)
Number of subjects: 80
Study: 10066854

Group type: EXPERIMENTAL
Intervention: Additional treatment by a qualified physiotherapist
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Additional treatment by a physiotherapy assistant
Number of subjects: 282

Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 282
Study: 8828605

Group type: EXPERIMENTAL
Intervention: Dietary restriction of phenylalanine (continued therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary restriction of phenylalanine (discontinued therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bender Gestalt test
Number of subjects: 0
Study: 1564674

Group type: EXPERIMENTAL
Intervention: Future oriented hypnotic imagery presented as hypnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future oriented hypnotic imagery not presented as hypnosis
Number of subjects: 0
Study: 3932499

Group type: EXPERIMENTAL
Intervention: 2% cromolyn sodium (CS) ophthalmic solution, used six times daily for 5 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo, used six times daily for 5 weeks
Number of subjects: 58
Study: 31701389

Group type: EXPERIMENTAL
Intervention: Threat-related beliefs
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Protective beliefs
Number of subjects: 248
Study: 29543938

Group type: EXPERIMENTAL
Intervention: TACE plus RT (maximum 45 Gy with fraction size of 2.5 to 3 Gy, every 6 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TACE plus RT
Number of subjects: 90

Group type: COMPARATOR
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 90
Study: 26414976

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for pain
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 113
Study: 24646637

Group type: EXPERIMENTAL
Intervention: Resin core build-up material, Gradia Core (Group 1A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-adhesive universal cement GCem Automix (Group 2B)
Number of subjects: 120
Study: 22389467

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 48
Study: 19813008

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) at 08:00
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) at 17:00
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) at 22:00
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) twice daily for 14 days at 08:00
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) twice daily for 14 days at 17:00
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 17624485

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme
Number of subjects: 183

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 183
Study: 16237691

Group type: EXPERIMENTAL
Intervention: CsA‐ME (C2 monitoring)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tacrolimus (C0 monitoring)
Number of subjects: 39
Study: 12389268

Group type: EXPERIMENTAL
Intervention: CHANGE intervention (Change Habits by Applying New Goals and Experiences); delivered through five small-group, nurse-led sessions during the last three weeks of CR and at one and two months following CR.
Number of subjects: 0
Study: 9952151

Group type: EXPERIMENTAL
Intervention: 2.0% lidocaine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 1.0% lidocaine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 109
Study: 7749977

Group type: EXPERIMENTAL
Intervention: Ebastine 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1546142

Group type: EXPERIMENTAL
Intervention: moclobemide, 450 mg/j
Number of subjects: 46

Group type: COMPARATOR
Intervention: viloxazine, 300 mg/j
Number of subjects: 46

Group type: COMPARATOR
Intervention: maprotiline, 150 mg/j
Number of subjects: 46
Study: 6375537

Group type: EXPERIMENTAL
Intervention: Propranolol (480 mg/day for 6 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil (480 mg/day for 6 weeks)
Number of subjects: 6
Study: 30898353

Group type: EXPERIMENTAL
Intervention: Milk protein-enriched beverage (MPB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate-enriched beverage (CB)
Number of subjects: 20
Study: 29898171

Group type: EXPERIMENTAL
Intervention: Experimental Auriculotherapy (G1)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Placebo Auriculotherapy (G2)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control (G3)
Number of subjects: 168
Study: 27381308

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal weight patients
Number of subjects: 0
Study: 25216649

Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) with pre-relax condition (FDI relaxed)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Continuous theta burst stimulation (cTBS) with pre-active condition (10% of maximal voluntary contraction)
Number of subjects: 36
Study: 22332827

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) at 59 μmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasopressin (VP) at 100 nmol/L
Number of subjects: 0
Study: 20688574

Group type: EXPERIMENTAL
Intervention: B vitamins (2 mg folic acid, 25 mg vitamin B6, and 0.5 mg vitamin B12)
Number of subjects: 8164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8164
Study: 18044297

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (bupivacaine 0.25% 6-10 ml + fentanyl 50-100 microg, followed by bupivacaine 0.125% + fentanyl 1-2 microg/ml at 6-12 ml/h)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 861
Study: 15642074

Group type: EXPERIMENTAL
Intervention: Conventional diet with agar
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 76
Study: 11816327

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA), initial dose of 10-15 mg/kg given 10-15 minutes before tourniquet release, with possible repeat doses every 6-8 hours during the first postoperative day.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study: 10094978

Group type: EXPERIMENTAL
Intervention: OMRI-Hep-B
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hepatect
Number of subjects: 15